Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014)
FT. Musuamba(Inserm), Ine Skottheim Rusten(Troms Kraft (Norway)), Norbert Benda(Federal Institute for Drugs and Medical Devices), Martin Posch(Medical University of Vienna), Robert Hemmings, S. Y. Amy Cheung(AstraZeneca (United Kingdom)), Scott Berry(Queen's University), Kristin Karlsson(Medical Products Agency), Valeria Gigante(World Health Organization), Andrew C. Hooker(Uppsala University), Justin L. Hay(System Simulation (United Kingdom)), Kayode Ogungbenro(University of Manchester), Anne Brochot(Ablynx (Belgium)), Thomas Dumortier(Novartis (United Kingdom)), Falk Ehmann, Björn Bornkamp(Novartis (Switzerland)), Susan Cole(European Medicines Agency), Joseph F. Standing(System Simulation (United Kingdom)), Shampa Das(AstraZeneca (United Kingdom)), Lena E. Friberg(Uppsala University), F Serone(Italian Medicines Agency), Solange Corriol‐Rohou(AstraZeneca (United Kingdom)), Frank Bretz(Novartis (Switzerland)), Nicholas H. G. Holford(University of Auckland), PH van der Graaf(Centre for Human Drug Research), JWT Yates(AstraZeneca (United Kingdom)), Efthymios Manolis(System Simulation (United Kingdom)), Neal Thomas(Pfizer (United States))
Cited by 68
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818